問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chung Shan Medical University Hospital (在職)

Division of Rheumatology

Division of General Internal Medicine

Division of Dermatology

更新時間：2023-09-19

魏正宗
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

35Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

魏正宗

Chung Shan Medical University Hospital

Division of Rheumatology

List

52Cases

2012-10-02 - 2015-12-31

Phase III

A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    Baricitinib (LY3009104)

Participate Sites
11Sites

Terminated10Sites

Study ended1Sites

2023-07-31 - 2026-04-30

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2021-04-30 - 2025-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2019-04-01 - 2022-06-20

Phase III

A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.

  • Condition/Disease

    Atopic Dermatitis

  • Test Drug

    Lebrikizumab

Participate Sites
7Sites

Recruiting7Sites

2011-09-01 - 2014-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2008-04-01 - 2010-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2021-04-01 - 2024-03-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2013-12-03 - 2020-08-10

Phase III

A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS

  • Condition/Disease

    PSORIATIC ARTHRITIS

  • Test Drug

    XELJANZ XR

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

2013-11-06 - 2017-07-31

Phase III

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO AT LEAST ONE TNF INHIBITOR

  • Condition/Disease

    PSORIATIC ARTHRITIS

  • Test Drug

    Xeljanz

Participate Sites
5Sites

Terminated5Sites

藍忠亮
China Medical University Hospital

2013-09-04 - 2017-09-15

Phase III

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) OR ADALIMUMAB IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS

  • Condition/Disease

    PSORIATIC ARTHRITIS

  • Test Drug

    Xeljanz

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB